-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Entero Therapeutics, Inc. quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q1 2024.
- Entero Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $0.000.
Deferred Income Tax Expense (Benefit), Quarterly (USD)